Biotech Acquisition Company
BIOTU
NASDAQ Capital Market10.14
USD
-0.05
- -
CIK
0001825413
ISIN
KYG1125A1242
CUSIP
G1125A124
Return %
Stock
S&P500
1Y
0.80
14.68
3Y
-1.65
82.78
5Y
-1.65
70.17
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Michael Shleifer
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 545 West 25th Street New York City NY United States of America 10001
- IPO Date
- Jan 22, 2021
- CIK
- 0001825413
- Similar Companies
- Business
- Biotech Acquisition Company (BIOTU) operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting opportunities in the biotechnology sector; it offers no current products or services beyond its SPAC structure, which includes public shares and warrants traded on Nasdaq and OTC markets. Founded in 2020 and headquartered in New York, New York, the company raised $230 million in its initial public offering on January 26, 2021, through units comprising one Class A ordinary share and one-half warrant, with 100% of proceeds held in trust; it conducted global operations with a 24-month tenor aimed at healthcare targets. In a major development, Biotech Acquisition Company entered a definitive merger agreement with Blade Therapeutics, Inc., a clinical-stage biopharmaceutical firm developing cudetaxestat, a non-competitive autotaxin inhibitor for idiopathic pulmonary fibrosis and systemic sclerosis, on November 8, 2021, filing a Form S-4 registration statement on March 16, 2022, to create Blade Biotherapeutics, Inc. (BBTX); however, the merger terminated in June 2022 due to failure to meet conditions, followed by an unsuccessful extension vote at an extraordinary general meeting on January 19, 2023, leading to dissolution and liquidation on February 3, 2023, with public shares redeemed at approximately $10.15 each from the trust account. Post-liquidation, BIOTU units continue trading on OTC markets at around $10.14 as of late 2025, reflecting residual warrant value and no further operational activity or new strategic initiatives.
Company News
Biotech Acquisition (OTCMKTS:BIOTU) Stock Falls 7.7% – What’s Next?
Biotech Acquisition (OTCMKTS:BIOTU) Trading Down 7.7% – Should You Sell?
Biotech Acquisition Company Announces Separate Trading of its Class A Ordinary Shares and Warrants Commencing March 18, 2021
Biotech Acquisition Company Announces Closing of $230,000,000 Initial Public Offering